Literature DB >> 30957057

Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers.

Michael Offin1, Romel Somwar2, Natasha Rekhtman2, Ryma Benayed2, Jason C Chang2, Andrew Plodkowski2, Allan J W Lui3, Juliana Eng1, Marc Rosenblum2, Bob T Li1, Gregory J Riely1, Charles M Rudin1, Mark G Kris1, William Travis2, Alexander Drilon1, Maria E Arcila2, Marc Ladanyi2, Helena A Yu1.   

Abstract

Entities:  

Year:  2018        PMID： 30957057      PMCID： PMC6447364          DOI： 10.1200/PO.18.00126

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  28 in total

1.  Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.

Authors:  Morana Vojnic; Daisuke Kubota; Christopher Kurzatkowski; Michael Offin; Ken Suzawa; Ryma Benayed; Adam J Schoenfeld; Andrew J Plodkowski; John T Poirier; Charles M Rudin; Mark G Kris; Neal X Rosen; Helena A Yu; Gregory J Riely; Maria E Arcila; Romel Somwar; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2019-03-01       Impact factor: 15.609

2.  High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.

Authors:  Ryma Benayed; Michael Offin; Kerry Mullaney; Purvil Sukhadia; Kelly Rios; Patrice Desmeules; Ryan Ptashkin; Helen Won; Jason Chang; Darragh Halpenny; Alison M Schram; Charles M Rudin; David M Hyman; Maria E Arcila; Michael F Berger; Ahmet Zehir; Mark G Kris; Alexander Drilon; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2019-04-26       Impact factor: 12.531

Review 3.  Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.

Authors:  Alissa J Cooper; Lecia V Sequist; Jessica J Lin
Journal:  Nat Rev Clin Oncol       Date:  2022-05-09       Impact factor: 65.011

Review 4.  Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?

Authors:  Elisa Bertoli; Elisa De Carlo; Alessandro Del Conte; Brigida Stanzione; Alberto Revelant; Kelly Fassetta; Michele Spina; Alessandra Bearz
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

5.  FGFR2::TACC2 fusion as a novel KIT-independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor.

Authors:  Josephine K Dermawan; Chad M Vanderbilt; Jason C Chang; Brian R Untch; Samuel Singer; Ping Chi; William D Tap; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2022-02-22       Impact factor: 4.263

6.  Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.

Authors:  Adam J Schoenfeld; Joseph M Chan; Daisuke Kubota; Hiroki Sato; Hira Rizvi; Yahya Daneshbod; Jason C Chang; Paul K Paik; Michael Offin; Maria E Arcila; Monika A Davare; Ujwal Shinde; Dana Pe'er; Natasha Rekhtman; Mark G Kris; Romel Somwar; Gregory J Riely; Marc Ladanyi; Helena A Yu
Journal:  Clin Cancer Res       Date:  2020-01-07       Impact factor: 12.531

Review 7.  Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.

Authors:  Catherine B Meador; Aaron N Hata
Journal:  Pharmacol Ther       Date:  2020-03-06       Impact factor: 12.310

8.  A Performance Comparison of Commonly Used Assays to Detect RET Fusions.

Authors:  Soo-Ryum Yang; Umut Aypar; Ezra Y Rosen; Douglas A Mata; Ryma Benayed; Kerry Mullaney; Gowtham Jayakumaran; Yanming Zhang; Denise Frosina; Alexander Drilon; Marc Ladanyi; Achim A Jungbluth; Natasha Rekhtman; Jaclyn F Hechtman
Journal:  Clin Cancer Res       Date:  2020-12-03       Impact factor: 12.531

Review 9.  Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer.

Authors:  Beatrice Gini; Nicholas Thomas; Collin M Blakely
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

Review 10.  Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.

Authors:  Alessandro Leonetti; Sugandhi Sharma; Roberta Minari; Paola Perego; Elisa Giovannetti; Marcello Tiseo
Journal:  Br J Cancer       Date:  2019-09-30       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.